Back

Mutational scanning reveals oncogenic CTNNB1 mutations have diverse effects on signalling and clinical traits

Krishna, A.; Meynert, A.; Kelder, M.; Ewing, A.; Sheraz, S.; Ferrer-Vacquer, A.; Grimes, G.; Becher, H.; Silk, R.; Semple, C. A.; Kendall, T.; Hadjantonakis, A.-K.; Bird, T.; Marsh, J. A.; Hohenstein, P.; Wood, A. J.; Ozdemir, D. D.

2023-11-13 cancer biology
10.1101/2023.11.09.566307 bioRxiv
Show abstract

CTNNB1, the gene encoding {beta}-catenin, is a frequent target for oncogenic mutations activating the canonical Wnt signalling pathway, typically via missense mutations within a degron hotspot motif in exon 3. Here, we combine saturation genome editing with a fluorescent reporter assay to quantify signalling phenotypes for all 342 missense mutations in the mutation hotspot, including 74 recurrent mutations reported in over 6000 tumours. Our data define the genetic requirements for {beta}-catenin degron function and reveal diverse levels of signal activation among known driver mutations. Tumorigenesis in different human tissues involves selection for CTNNB1 mutations spanning distinct ranges of effect size. In hepatocellular carcinoma, mutations that activate {beta}-catenin relatively weakly are associated with worse prognosis compared to stronger activating mutations, despite greater immune cell infiltration in the tumour microenvironment. Our work therefore provides a resource to understand mutational diversity within a pan-cancer mutation hotspot, with potential implications for targeted therapy.

Matching journals

The top 8 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.